Cerus Corp CERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
-
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
-
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
-
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
Trading Information
- Previous Close Price
- $1.78
- Day Range
- $1.74–1.83
- 52-Week Range
- $1.21–2.59
- Bid/Ask
- $1.74 / $1.75
- Market Cap
- $324.27 Mil
- Volume/Avg
- 840,104 / 958,862
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.05%
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 280
- Website
- https://www.cerus.com
Comparables
Valuation
|
Metric
|
CERS
|
300896
|
000403
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 29.08 | 21.97 |
Price/Book Value | 6.55 | 8.51 | 2.20 |
Price/Sales | 1.88 | 22.08 | 6.04 |
Price/Cash Flow | 100.93 | 32.22 | 18.29 |
Price/Earnings
CERS
300896
000403
Financial Strength
|
Metric
|
CERS
|
300896
|
000403
|
|---|---|---|---|
Quick Ratio | 1.76 | 15.24 | 2.45 |
Current Ratio | 2.51 | 16.84 | 3.72 |
Interest Coverage | −1.62 | 1,119.23 | 749.08 |
Quick Ratio
CERS
300896
000403
Profitability
|
Metric
|
CERS
|
300896
|
000403
|
|---|---|---|---|
Return on Assets (Normalized) | −2.84% | 28.38% | 8.89% |
Return on Equity (Normalized) | −11.06% | 30.49% | 10.33% |
Return on Invested Capital (Normalized) | 1.15% | 28.94% | 8.96% |
Return on Assets
CERS
300896
000403
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Dwjcxlcxn | Zscqt | $195.6 Bil | |||
| Stryker Corp
SYK
| Pvmpjhkkkt | Zjrxk | $137.3 Bil | |||
| Boston Scientific Corp
BSX
| Wcsfsrk | Jnscrq | $122.7 Bil | |||
| Medtronic PLC
MDT
| Qkcsndfw | Mswxwb | $114.6 Bil | |||
| Edwards Lifesciences Corp
EW
| Vlbwvnvkv | Rzsyfq | $40.1 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Vmqnt | Hgfx | $30.7 Bil | |||
| DexCom Inc
DXCM
| Wfvmdqdh | Cndq | $27.0 Bil | |||
| Steris PLC
STE
| Xhxmqddhl | Gmlfnq | $23.6 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Dxncylvnr | Grphc | $22.0 Bil | |||
| Insulet Corp
PODD
| Fbskcxmfj | Cyclxgl | $16.3 Bil |
United States